SOLOIST

Objective

The purpose of the study is to show that sotagliflozin can decrease the risk of cardiovascular death, or decreases the risk of being hospitalized for heart failure.

SOLOIST is a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemodynamIcally STable Patients with Type 2 Diabetes POST Worsening Heart Failure.

Location:

Essentia Health East

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 05/29/2019

Research Study Categories

  • Adult Studies

Specialty

  • Cardiology
  • Heart Failure
Contact
Cardiology Clinical Trials at 866-839-4128
or clinicaltrials@essentiahealth.org